HIPEC in Gastric Cancer: Prophylactic and Therapeutic Roles Explained

Hyperthermic intraperitoneal chemotherapy in gastric cancer requires a strict distinction between prophylactic and therapeutic interventions within contemporary multimodal management, according to recent medical literature published in Cureus on August 25, 2026. The clinical review highlights how heated chemotherapy delivered directly into the abdominal cavity serves different patient populations depending on whether it targets microscopic disease prevention or active peritoneal carcinomatosis.

Prophylactic Versus Therapeutic Clinical Roles

The application of hyperthermic intraperitoneal chemotherapy, commonly known as HIPEC, splits into two distinct clinical strategies for gastric cancer patients. Prophylactic administration aims to prevent peritoneal recurrence in patients deemed at high risk for metastasis but without active peritoneal seeding during exploration. Conversely, therapeutic application treats established peritoneal carcinomatosis with the goal of cytoreductive surgery combined with heated drug delivery to eradicate macroscopic and microscopic disease remaining in the abdomen.

According to the Cureus study, blending these two divergent indications complicates clinical trial design and distorts survival outcomes in contemporary literature. Researchers emphasize that patient selection criteria must separate individuals receiving treatment for established metastatic disease from those undergoing preventive protocols during primary resection.

Integration Into Multimodal Management Protocols

Modern treatment pathways for advanced gastric cancer increasingly rely on multimodal approaches that combine systemic chemotherapy, surgical resection, and specialized regional therapies like HIPEC. The heated intraoperative bath allows surgeons to deliver high concentrations of chemotherapeutic agents directly to peritoneal surfaces while minimizing systemic toxicity, though thermal and pharmacological parameters require precise standardization across medical centers.

Data from the review underscore that surgical completeness, specifically achieving a complete cytoreduction with no macroscopic residual disease, remains a primary determinant of survival in therapeutic cohorts. For prophylactic applications, the focus centers on identifying reliable preoperative biomarkers and staging laparoscopy findings that accurately predict high peritoneal recurrence risk without exposing low-risk patients to added morbidity.